Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344155 | 0.78 | PYCR1 (0.35) | PYCR1 | |
| SCHEMBL5158400 | 0.77 | SIGMAR1 (0.36) | PYCR1ALDH1A1MAPK1SIGMAR1NPSR1 | |
| SCHEMBL290236 | 0.77 | TSHR (0.48) | PYCR1 | |
| SCHEMBL7932663 | 0.77 | MAPT (0.33) | ALDH1A1MAPT | |
| SCHEMBL29661807 | 0.76 | HSP90AA1 (0.46) | PYCR1ALDH1A1MAPK1CYP2A6AHR | |
| SCHEMBL30150790 | 0.76 | TDP1 (0.42) | PYCR1ALDH1A1CYP2A6NPSR1RAPGEF4 | |
| SCHEMBL4746042 | 0.76 | HSP90AA1 (0.46) | PYCR1ALDH1A1MAPK1CYP2A6AHR | |
| SCHEMBL935347 | 0.76 | TDP1 (0.42) | PYCR1ALDH1A1CYP2A6NPSR1RAPGEF4 | |
| SCHEMBL16533986 | 0.76 | PYCR1 (0.35) | PYCR1ALDH1A1MAPK1SIGMAR1NPSR1 | |
| SCHEMBL3841101 | 0.74 | HDAC8 (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180123-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9018384-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2512474-B1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8846933-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664401-B2 | N-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2512474-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. | 2012-10-11 | — | — | US | disclosed |
| WO-2011073845-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | PYCR1 1391/4885ALDH1A1 3989/4885MAPK1 2617/4885 |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, LCT, HAX1 | PYCR1 1849/4885ALDH1A1 2520/4885MAPK1 3357/4885 |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | PYCR1 1391/4885ALDH1A1 3989/4885MAPK1 2617/4885 |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | PYCR1 1391/4885ALDH1A1 3989/4885MAPK1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.